<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1999</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭПИДЕМИОЛОГИЯ И ПРОФИЛАКТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EPIDEMIOLOGY AND PREVENTION</subject></subj-group></article-categories><title-group><article-title>Распространенность и особенности проявлений метаболического синдрома во взрослой городской популяции</article-title><trans-title-group xml:lang="en"><trans-title>Prevalence and specific features of metabolic syndrome in urban adult population</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Токарева</surname><given-names>З. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tokareva</surname><given-names>Z. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный специалист по профилактики Минздравсоцразвития Чувашской Республики</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамедов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamedov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>руководитель лаборатории прогнозирования и оценки сердечно-сосудистого риска</p></bio><email xlink:type="simple">mmamedov@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деев</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Deev</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>руководитель лаборатории биостатистики</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евдокимова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Evdokimova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный терапевт Минздравсоцразвития Чувашской Республики</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оганов</surname><given-names>Р. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Oganov</surname><given-names>R. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>директор</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГУ Государственный научно-исследовательский центр профилактической медицины Росмедтехнологий<country>Россия</country></aff><aff xml:lang="en">State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2010</year></pub-date><volume>9</volume><issue>1</issue><fpage>10</fpage><lpage>14</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Токарева З.Н., Мамедов М.Н., Деев А.Д., Евдокимова А.А., Оганов Р.Г., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Токарева З.Н., Мамедов М.Н., Деев А.Д., Евдокимова А.А., Оганов Р.Г.</copyright-holder><copyright-holder xml:lang="en">Tokareva Z.N., Mamedov M.N., Deev A.D., Evdokimova A.A., Oganov R.G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1999">https://cardiovascular.elpub.ru/jour/article/view/1999</self-uri><abstract><p>Цель. Изучить распространенность и особенности клинической симптоматики метаболического синдрома (МС) в случайной выборке взрослого населения отдельно взятого города. Материал и методы. Методом случайной выборки в исследование были включены 749 мужчин и 1051 женщина в возрасте 30-69 лет (n=1800). Полностью обследование завершили 620 мужчин и 950 женщин (n=1570) – 87,2% от исходного числа респондентов. Все респонденты опрошены по стандартному вопроснику; у всех определены антропометрические показатели, артериальное давление (АД), уровень липидов крови, гликемия натощак и через 2 часа после нагрузки. Результаты. По критериям NCEP ATP III МС выявлен у 314 человек (20,6%), по критериям МФД МС – у 447 (28,5%) (p&lt;0,0001). В целом, среди женщин МС встречается в 2 раза чаще. С возрастом среди мужчин и женщин число лиц с МС увеличивается. Наибольшее число пациентов с МС имеют три его компонента (61,5%), у 28,7% пациентов выявлены 4 компонента МС, тогда как полный МС обнаружен у 9,8% обследованных. Компоненты МС встречаются в следующей последовательности: 68,8% – низкий уровень холестерина липопротеидов высокой плотности, 65,3% – гипертриглицеридемия, 65% – абдоминальное ожирение (АО) по критериям ATP III, 65% – АГ и 45,2% – гипергликемия. Каждый третий респондент с МС на момент обследования имел те или иные клинические проявления атеросклероза, включая ишемическую болезнь сердца, инфаркт миокарда в анамнезе, периферический атеросклероз и атеросклероз сосудов головного мозга. Заключение. Среди лиц трудоспособного возраста МС встречается в 20% случаев. Наиболее частыми его компонентами являются дислипидемия, АГ и АО. На момент обследования у каждого третьего пациента имели место различные варианты сердечно-сосудистых заболеваний.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the prevalence and specific clinical features of metabolic syndrome (MS) in a random sample of urban adult population. Material and methods. In total, 1800 participants were randomly selected: 749 men and 1051 women, aged 30-69 years. The study protocol was completed by 1570 subjects: 620 men and 950 women (response rate 87,2%). All participants underwent standard questionnaire survey, anthropometry, and the measurement of blood pressure (BP), blood lipids, and blood glucose (fasting glycemia and glycemia at 2 hours after oral glucose tolerance test). Results. According to the NCEP ATP III criteria, MS was registered in 314 participants (20,6%), and according to the IDF criteria – in 447 (28,5%; p&lt;0,0001). On average, MS was twice as prevalent in women as in men. In both genders, advanced age was associated with increasing MS prevalence. The majority of the participants had three MS components (61,5%). Four MS components were registered in 28,7%, and all the components were observed in 9,8%. The most prevalent MS component was low level of high-density lipoprotein cholesterol (68,8%), followed by hypertriglyceridemia (65,3%), abdominal obesity by ATP III criteria (65%), arterial hypertension, AH (65%), and hyperglycemia (45,2%). Each third respondent with MS demonstrated clinical manifestations of atherosclerosis, such as coronary heart disease, myocardial infarction in anamnesis, peripheral or cerebrovascular atherosclerosis. Conclusion. Among this working-age population, MS prevalence was 20%. The most common MS components included dyslipidemia, AH, and abdominal obesity. Each third MS patient had various manifestations of cardiovascular pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>метаболический синдром</kwd><kwd>распространенность</kwd><kwd>сердечно-сосудистый риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Metabolic syndrome</kwd><kwd>prevalence</kwd><kwd>cardiovascular risk</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология 2004; 44(9): 4-8.</mixed-citation><mixed-citation xml:lang="en">Мамедов М.Н., Оганов Р.Г. Эпидемиологические аспекты метаболического синдрома. Кардиология 2004; 44(9): 4-8.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37; 1595-607.</mixed-citation><mixed-citation xml:lang="en">Reaven G. Role of insulin resistance in human disease. Diabetes. 1988; 37; 1595-607.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Isomaa B., Almgren P., Tuomi T., Forsen B. Cardiovascular morbidity and mortality associated with the metabolic syndrome (Botnia Study). Diabetes Care 2001; 24(4): 683-9.</mixed-citation><mixed-citation xml:lang="en">Isomaa B., Almgren P., Tuomi T., Forsen B. Cardiovascular morbidity and mortality associated with the metabolic syndrome (Botnia Study). Diabetes Care 2001; 24(4): 683-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program. JAMA 2001; 285: 2486-97.</mixed-citation><mixed-citation xml:lang="en">Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program. JAMA 2001; 285: 2486-97.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9.</mixed-citation><mixed-citation xml:lang="en">Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Balkau B., Charles M.A., Drivsholm T., et al. Frequence of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28(5): 364-76.</mixed-citation><mixed-citation xml:lang="en">Balkau B., Charles M.A., Drivsholm T., et al. Frequence of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28(5): 364-76.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">L'italien G., Kan H. The metabolic syndrome as an independent predictor of diabetes, cardiovascular disease and all cause mortality: a meta-analysis of recent studies. J Diabetes 2009; l(Suppll):A83.</mixed-citation><mixed-citation xml:lang="en">L'italien G., Kan H. The metabolic syndrome as an independent predictor of diabetes, cardiovascular disease and all cause mortality: a meta-analysis of recent studies. J Diabetes 2009; l(Suppll):A83.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jones E.D., Ivanov L.L., Wallace D.C., VonCannon L. Examining the metabolic syndrome in Russia. Int J Nurs Pract 2006; 12(5): 260-6.</mixed-citation><mixed-citation xml:lang="en">Jones E.D., Ivanov L.L., Wallace D.C., VonCannon L. Examining the metabolic syndrome in Russia. Int J Nurs Pract 2006; 12(5): 260-6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetes Med 2007; 24: 451-63.</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetes Med 2007; 24: 451-63.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Алмазов В., Благосклонная Я., Шляхто Е., Красильникова Е. Метаболический сердечно-сосудистый синдром. Санкт Петербург 1999; 8-12, 68, 157-61.</mixed-citation><mixed-citation xml:lang="en">Алмазов В., Благосклонная Я., Шляхто Е., Красильникова Е. Метаболический сердечно-сосудистый синдром. Санкт Петербург 1999; 8-12, 68, 157-61.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ford E.S., Li С., Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31(9): 1898-904.</mixed-citation><mixed-citation xml:lang="en">Ford E.S., Li С., Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31(9): 1898-904.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">McNeil A., Rosamond W., Girman C., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 285-390.</mixed-citation><mixed-citation xml:lang="en">McNeil A., Rosamond W., Girman C., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 285-390.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедов М.Н. Метаболический синдром -больше, чем сочетание факторов риска: принципы диагностики и лечения. Издание "Верваг фарма". Москва 2006; 7-42.</mixed-citation><mixed-citation xml:lang="en">Мамедов М.Н. Метаболический синдром -больше, чем сочетание факторов риска: принципы диагностики и лечения. Издание "Верваг фарма". Москва 2006; 7-42.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Alberti K.G., Zimmet P., Shaw I. The metabolic syndrome -a new worldwide definition. Lancet 2005; 366: 1059-62.</mixed-citation><mixed-citation xml:lang="en">Alberti K.G., Zimmet P., Shaw I. The metabolic syndrome -a new worldwide definition. Lancet 2005; 366: 1059-62.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic med 2003; 20(9): 693-702.</mixed-citation><mixed-citation xml:lang="en">Zimmet P., Shaw J., Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic med 2003; 20(9): 693-702.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Saely C.H., Vonbank A., Rein P. Adult treatment Panel III metabolic syndrome criteria more strongly than international diabetes federation criteria predict the incidence of type 2 diabetes in angiographied coronary patients. J Diabetes 2009; l(Suppl 1):A84.</mixed-citation><mixed-citation xml:lang="en">Saely C.H., Vonbank A., Rein P. Adult treatment Panel III metabolic syndrome criteria more strongly than international diabetes federation criteria predict the incidence of type 2 diabetes in angiographied coronary patients. J Diabetes 2009; l(Suppl 1):A84.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
